Mir Hashim
2022
In 2022, Mir Hashim earned a total compensation of $2.3M as Chief Scientific Officer at Rani Therapeutics Holdings, a 54% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $249,600 |
|---|---|
| Option Awards | $1,114,129 |
| Salary | $412,000 |
| Stock Awards | $544,252 |
| Total | $2,319,981 |
Hashim received $1.1M in option awards, accounting for 48% of the total pay in 2022.
Hashim also received $249.6K in non-equity incentive plan, $412K in salary and $544.3K in stock awards.
Rankings
In 2022, Mir Hashim's compensation ranked 1,546th out of 5,625 executives tracked by ExecPay. In other words, Hashim earned more than 72.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,546 out of 5,625 | 73rd |
Division Manufacturing | 783 out of 3,053 | 74th |
Major group Chemicals And Allied Products | 304 out of 1,380 | 78th |
Industry group Drugs | 282 out of 1,281 | 78th |
Industry Pharmaceutical Preparations | 200 out of 927 | 78th |
Source: SEC filing on April 11, 2023.
Hashim's colleagues
We found two more compensation records of executives who worked with Mir Hashim at Rani Therapeutics Holdings in 2022.